We are pleased to announce that our invested company I-Mab (Nasdaq: IMAB) has been selected as a constituent stock of the MSCI China All Shares Index. The MSCI China All Shares Index is widely followed and closely tracked by global investors as a major benchmark for China equity exposure. The inclusion will be implemented as of market close on May 27, 2021.

Mr. Jielun Zhu, Director and Chief Financial Officer of I-MAB, commented that becoming a constituent in the MSCI China Index is another significant capital markets milestone, after the inclusion in the NASDAQ Biotechnology Index in December 2020. The Company is one of the very few China biotech stocks added to this bellwether index, further demonstrating I-Mab’s growing profile and recognition among the global investor communities.

I-Mab is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company is strongly positioned to deliver even greater value to shareholders as it continues to build on its competitive innovative assets, from the near-term NDA filing of felzartamab (CD38 antibody) to important data readouts of lemzoparlimab (CD47 antibody) and uliledlimab (CD73 antibody).

I-MAB was successfully listed on the Nasdaq on January 17, 2020. Its share price skyrocketed 340% from US$14/share to US$62.08/share as of May 13, 2021. It is our pleasure that we are able to participate in its C1 round of financing in 2019.

If you would like to hear the latest updates on the Firm and the Fund, please feel free to contact our Investor Relations team at IR@VMSIG.COM.